Timberlyne Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for autoimmune disorders. The company is advancing CM313, a monoclonal antibody targeting CD38, aimed at addressing diseases with high unmet medical needs. Formed through a partnership between Mountainfield Venture Partners and Keymed Biosciences, Timberlyne Therapeutics holds global development and commercial rights for CM313 outside of greater China.
Key Executives
Timberlyne Therapeutics had 7 employees as of October 12, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Timberlyne Therapeutics had 3,155 followers as of October 12, 2026. The number of followers increased by 8 (0.25%) week-over-week.
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jan 10, 2025 | Series A | $180.00M | ― |
| Investor Name | Funding Round |
|---|---|
| Braidwell LP | Series A |
| Venrock Healthcare Capital Partners | Series A |
| Abingworth | Series A |
| Bain Capital Life Sciences | Series A |
| Boyu Capital | Series A |
| Lilly Asia Ventures | Series A |
| 3H Health Investment | Series A |
A snapshot of private companies similar to Timberlyne Therapeutics, helping you discover and navigate related company profiles.



